Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-03
2007-04-03
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S253000
Reexamination Certificate
active
10829873
ABSTRACT:
Provided are process for the preparation of valsartan and the precursors thereof.
REFERENCES:
patent: 5260325 (1993-11-01), Markwalder et al.
patent: 5399578 (1995-03-01), Buhlmayer et al.
patent: 5965592 (1999-10-01), Buhlmayer et al.
patent: 6271375 (2001-08-01), Villa et al.
patent: 6294197 (2001-09-01), Wagner et al.
patent: 6395728 (2002-05-01), Webb et al.
patent: 6465502 (2002-10-01), Bullock et al.
patent: 6485745 (2002-11-01), Wagner et al.
patent: 2002/0132839 (2002-09-01), Ganter et al.
patent: 2003/0035832 (2003-02-01), Katakuse et al.
patent: 2003/0152620 (2003-08-01), Ganter et al.
patent: 2003/0207930 (2003-11-01), Marti et al.
patent: 2004/0072886 (2004-04-01), Reguri et al.
patent: 2004/0242661 (2004-12-01), Rukhman, et al.
patent: 2005/0059827 (2005-03-01), Rukhman, et al.
patent: 0 570 091 (1993-11-01), None
patent: 0 443 983 (1996-02-01), None
patent: WO 97/30036 (1997-08-01), None
patent: WO 99/001459 (1999-01-01), None
patent: WO 99/67231 (1999-12-01), None
patent: WO 01/82858 (2001-11-01), None
patent: WO 01/82858 (2001-11-01), None
patent: WO 02/06253 (2002-01-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/089417 (2003-10-01), None
patent: WO 2004026847 (2004-04-01), None
patent: WO 2004/083192 (2004-09-01), None
patent: WO 2004/087681 (2004-10-01), None
patent: WO 2004/094392 (2004-11-01), None
U.S. Appl. No. 10/802,627.
Peter Buhlmayer, et al.,Bioorgan.&Med. Chem. Lett.,4(1), 29-34 (1994).
Th.Moenius, et al.,J.Labelled Cpd. Radiopharm., 43(13) 1245-1252 (2000).
Qingzhong Jia, et al.,Zhongguo Yiyao Gongye Zazhi, 32(9) 385-387 (2001).
Borka L., et al., “Crystal Polymorphism of Pharmaceuticals”,Acta Pharm. Jugosl.,40, (1990) 71-94.
Merck Index (12thEdition, p. 1691, Valsartan n. 10051).
Zhong Guo, et al.,Chinese Journal of Pharmaceuticals, 2002, pp. 385-387, vol. 32, Part 9.
Dolitzky Ben-Zion
Flyaks Evgeni
Rukhman Igor
Chung Susannah L.
Kenyon & Kenyon LLP
Saeed Kamal A.
Teva Pharmaceuticals Industries Ltd.
LandOfFree
Process for the preparation of valsartan and intermediates... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the preparation of valsartan and intermediates..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the preparation of valsartan and intermediates... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3767222